SRX 246

Drug Profile

SRX 246

Alternative Names: API 246; SRX246

Latest Information Update: 16 Feb 2017

Price : $50

At a glance

  • Originator Azevan Pharmaceuticals
  • Class Heart failure therapies; Neuropsychotherapeutics; Small molecules
  • Mechanism of Action Vasopressin 1a receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Impulse control disorders; Post-traumatic stress disorders
  • Phase I/II Behavioural disorders
  • Phase I Anxiety disorders

Most Recent Events

  • 03 Feb 2017 Phase-I clinical trials in Anxiety disorders (In volunteers) in USA (PO) (NCT02922166)
  • 27 Jan 2017 The National Institute of Mental Health plans a phase I trial in Healthy volunteers in USA (PO) (NCT03036397)
  • 01 Dec 2016 Phase-II clinical trials in Post-traumatic stress disorder in USA (PO) (NCT02733614)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top